Puma Biotechnology hosted a conference call and provided a corporate update on May 7, 2026, following release of its 1Q-2026 ...

Preliminary response data for VIR-5818 (HER2-targeted) and VIR-5525 (EGFR-targeted) are expected in 2026 to inform dose ...

(Michael on for Roanna Ruiz), Leerink Partners: "what would constitute a clear signal as a green light to initiate Phase III in 2027?"; President, CEO & Director De Backer: "it's going to really be ...

Beneath the beauty of coral reefs lies a hidden universe of microbes unlike anything scientists expected. Each coral species ...

(PBYI) on Thursday reported a loss of $3.8 million in its first quarter. The Los Angeles-based company said it had a loss of 7 cents ...

Virginia has invested in recent years to become a leader in biotechnology. This week, city and state leaders cut the ribbon ...

From the company that restored the dire wolf species comes an ambitious project to bring a long-extinct South African animal ...

HANGZHOU, China, May 8, 2026 /PRNewswire/ -- Chance Pharmaceuticals ("Chance" or "Chance Pharma"), a clinical-stage biotechnology company dedicated to the research and development of innovative ...

Odyssey Therapeutics Inc. raised $304 million in an upsized US initial public offering priced at the top of a marketed range, ...

Dive deeper with STAT+. Gain unlimited access to expert analysis, newsletters, events, and news alerts.

G&A expenses were $10.8 million for the first quarter of 2026, compared to $8.8 million for the first quarter of 2025. The increase was primarily due to an increase in compensation expense, including ...

The companies developing Ebvallo reached an agreement with the FDA to address its main reason for rejecting the drug.